In summary, we identified ICAM1 could be a molecular therapeutic target for CCA and validated its therapeutic potential by constructing two rational ICAM1 ADCs, ICAM1-MMAE and ICAM1-DXd. Here, ICAM1 is linked to cholangiocarcinoma.